Shorter radiation combo may boost rectal cancer remission

NCT ID NCT07469306

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments for locally advanced rectal cancer: a shorter course of radiation plus chemotherapy (CAPOX) and immunotherapy (tislelizumab) versus a longer course of chemoradiation plus the same immunotherapy. The goal is to see which approach leads to a higher rate of complete tumor disappearance. About 130 adults aged 18-75 with a specific type of rectal cancer will participate.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Jinjiang Municipal Hospital

    Quanzhou, Fujian, 362200, China

    Contact Phone: •••-•••-••••

  • The Second Hospital of Longyan

    Longyan, Fujian, 364000, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••